ERBB2 and breast cancer: In the phase II NA-PHER2 study, patients with HR-positive and HER2-positive BC were treated every 3 weeks with intravenous trastuzumab and pertuzumab for 6 cycles, plus oral palbociclib and intramuscular fulvestrant every 4 weeks for 5 cycles.